Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Paul W O'Connor"'
Autor:
Jiwon Oh, Paul W. O’Connor
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 7 (2014)
A number of novel oral agents are now approved for use in relapsing multiple sclerosis (MS). Among these agents, teriflunomide has shown promise with respect to clinical efficacy and safety in relapsing MS patients. In this review we aim to clarify t
Externí odkaz:
https://doaj.org/article/cc13836615da413aae1f2bdcae6628ed
Autor:
James J. Marriott, Paul W. O'Connor
Publikováno v:
Reviews on Recent Clinical Trials(Online). 999:1-10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::798f24bb297ce21a3de16bd20b7c0385
https://doi.org/10.2174/1574210205001478871
https://doi.org/10.2174/1574210205001478871
Autor:
Jiwon, Oh, Paul W, O'Connor
Publikováno v:
Nature reviews. Neurology. 11(2)
Scientific progress in multiple sclerosis (MS) research spanned a number of areas in 2014, including therapeutics, disease classification, risk management, and disease mechanisms. Advances were particularly notable in the field of progressive MS. Alt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cef2f65d4ee4f0c10e04000dcca7033a
https://pubmed.ncbi.nlm.nih.gov/25582444
https://pubmed.ncbi.nlm.nih.gov/25582444
Autor:
Paul W, O'Connor, Jiwon, Oh
Publikováno v:
Handbook of clinical neurology. 122
Over the past two decades, major advances have been made in the development of disease-modifying agents (DMAs) for multiple sclerosis (MS), and nine agents are now licensed for use in the treatment of MS in the United States. Clinical trials have dem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6832dc2e8f18485be7aa108307cb40ea
https://pubmed.ncbi.nlm.nih.gov/24507532
https://pubmed.ncbi.nlm.nih.gov/24507532
Autor:
Jiwon, Oh, Paul W, O'Connor
Teriflunomide is a novel disease-modifying agent that was recently approved for use in the treatment of multiple sclerosis (MS). Teriflunomide has demonstrated clinical efficacy and safety in a number of large, multicenter, phase III clinical trials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad64bc16774703667e419a4596e844f3
https://europepmc.org/articles/PMC3721245/
https://europepmc.org/articles/PMC3721245/
Autor:
Paul W. O’Connor
Glatiramer acetate (GA) seems to affect immune cells in an antigenic specific way, and could be considered as an example of a therapeutic vaccination, as opposed to the prophylactic vaccinations commonly used for infectious diseases. The first human
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1fcbeb7a00448ffb0e61973375783c3d
https://doi.org/10.1017/cbo9781139023986.038
https://doi.org/10.1017/cbo9781139023986.038
Autor:
Richard A, Rudick, Paul W, O'Connor, Chris H, Polman, Andrew D, Goodman, Soma S, Ray, Nancy M, Griffith, Stephanie A, Jurgensen, Leonid, Gorelik, Fiona, Forrestal, Alfred W, Sandrock, Susan E, Goelz
Publikováno v:
Annals of neurology. 68(3)
Analyses were conducted to determine the clinical utility of measuring JC virus (JCV) DNA in blood or urine of natalizumab-treated multiple sclerosis (MS) patients to predict the risk of progressive multifocal leukoencephalopathy (PML).A total of 12,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::902dd400051df523ddaa30da34a6b8c7
https://pubmed.ncbi.nlm.nih.gov/21280097
https://pubmed.ncbi.nlm.nih.gov/21280097
Autor:
Nuhad E. Abou Zeid, Alberto Ascherio, Brenda Banwell, Angela Bates, Tamir Ben-Hur, Allen C. Bowling, Scott L. Davis, Philip L. De Jager, Ranjan Dutta, Gilles Edan, Elliot M. Frohman, Teresa C. Frohman, Ralf Gold, David A. Hafler, Anu Jacob, Ilijas jelČiĆ, Adam I. Kaplin, Douglas A. Kerr, Christoph Kleinschnitz, Dana E. Kozubal, Gary E. Lemack, Ralf A. Linker, Claudia F. lucchinetti, James J. Marriott, Roland Martin, Marcelo Matiello, Nico Melzer, Sven G. Meuth, Sean P. Morrissey, Kassandra L. Munger, Paul W. O'Connor, Maria Pia Amato, Istvan Pirko, Sean Joseph Pittock, Alexandra Schröder, Anjali Shah, Bruce D. Trapp, Carrilin C. Trecker, Sunita Venkateswaran, Rhonda Voskuhl, Brian G. Weinshenker, Heinz Wiendl, Dean M. Wingerchuk, Nathan P. Young, Valentina Zipoli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b57fdf3d954e9339bb72ecb2277ac742
https://doi.org/10.1016/b978-1-4160-6068-0.00024-3
https://doi.org/10.1016/b978-1-4160-6068-0.00024-3
Autor:
Ludwig Kappos, David Bates, Hans-Peter Hartung, Eva Havrdova, David Miller, Chris H Polman, Mads Ravnborg, Stephen L Hauser, Richard A Rudick, Howard L Weiner, Paul W O'Connor, John King, Ernst Wilhelm Radue, Tarek Yousry, Eugene O Major, David B Clifford
Publikováno v:
The Lancet. Neurology. 6(5)
Natalizumab is a new treatment option for patients with active relapsing-remitting multiple sclerosis. In phase III studies, natalizumab was highly effective and well tolerated; however, three cases of progressive multifocal leucoencephalopathy (PML)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74cbc7e3b302396726a6630e8721a5cc
https://pubmed.ncbi.nlm.nih.gov/17434098
https://pubmed.ncbi.nlm.nih.gov/17434098